VDR and breast carcinoma: Taken together these observations and the fact that the VDR and EAG1 are expressed in 90% and 85%; respectively, of breast cancer tumors[18–21], we hypothesized that a combined treatment targeting these two proteins in vivo could result in an improved therapeutic benefit for breast cancer management, including those tumors not treatable by hormonal therapy.